as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
Eisai Co.,Ltd.(Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced the presentation and discussion? about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat* research data on Alzheimer’s disease (AD), were given in the AAIC’s Focused Topic Session “Discussion of BACEi Trial Findings: Challenges and Opportunities” at the Alzheimer’s Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019. In addition, Eisai held a symposium focused on the rationale and opportunities for drug development for pre-clinical AD.
Eisai Co.,Ltd.(Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that data relating to a new anti-tau antibody E2814*1?was presented at the Alzheimer’s Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019 (Poster Presentation No.: P4-696).
Eisai Co.,Ltd.(Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced its latest research on evaluation about correlation of amyloid beta (Aβ) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation (Headquarters: Hyogo, Chairman and CEO: Hisashi Ietsugu, “Sysmex”), using full-automated immunoassay system HISCLTM*1?series for creating the simplified diagnosis of Alzheimer’s disease (AD) with blood was presented at the Alzheimer’s Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019. (Poster Presentation No.: P4-548)
Eisai Co.,Ltd.(Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced its latest data of nonclinical research which examined the effect to the synaptic function in the brain by spinal densities*1?in regard to oral BACE (beta-site amyloid precursor protein cleaving enzyme) inhibitor elenbecestat*2?were presented at the Alzheimer’s Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019 (Poster Presentation No.: P2-064).
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that Eisai received New Drug Approval for Eisai’s in-house developed anticancer agent eribulin mesylate (Halaven?) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration (NMPA).?
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been included in the FTSE4Good Index Series for the 18th consecutive year since its initial inclusion in 2002.? The FTSE4Good Index Series is a global index series for socially responsible investment.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities.
July 3, 2019 – Eisai China Inc. announced that it would again donate 350,000 yuan to China Population Welfare Foundation for the project “Public Welfare Stars Invite You to Help the Elderly with Cognitive Impairment Go Home”, which was jointly organized by China Population Welfare Foundation and Tencent News.?
On June 24, 2019, Eisai China Inc. was invited to participate in the “Health to Countryside” activity, which was organized by the Education, Science, Health and Sports Committee of CPPC in Qinghai Province, and donated drugs worth of about RMB 530,000 yuan to the Qinghai Red Cross Society, which will be used in the “Health to Countryside” activity in Qinghai Province. Eisai China has always been adhering to its?hhc?(human health care) corporate philosophy, actively participating in charitable activities and bearing its social responsibilities. From 2014 to 2019, we have donated medicines worth of about RMB 3 million yuan through the “Health to Countryside” campaign.
